Twelve patients with angina pectoris were evaluated in a single blind crossover study with respect to objective changes in exercise performance on the treadmill and subjective, clinical improvement on oral administration of propranolol, isosorbide dinitrate (ISD), and a combination of propranolol and ISD. Combined objective and subjective evaluations showed that nine of 12 patients improved on propranolol, seven of 10 on ISD, and all 10 on the combination of drugs. The differences in objective improvement between the various drug regimens were not significant. However, subjectively all patients on the combination of drugs improved markedly. The patients on propranolol or the combination had a decrease in pressure-rate index of about 30% both at rest and during exercise, while these values did not change on ISD. A significant reduction in exercise-induced S-T depression was observed with propranolol alone and in combination with ISD at grade 3+ pain. Adrenergic activity, estimated from plasma and urinary catecholamines, appeared to be increased in these patients before drug treatment and was not altered during treatment. It is concluded that propranolol, ISD, and the combination of these drugs all improve exercise performance in patients with angina. Although the combination of drugs could not be shown to produce a greater increase in exercise performance than either drug alone, the combination effected a greater overall clinical improvement. 
jectively all patients on the combination of drugs improved markedly. The patients on propranolol or the combination had a decrease in pressure-rate index of about 30% both at rest and during exercise, while these values did not change on ISD. A significant reduction in exercise-induced S-T depression was observed with propranolol alone and in combination with ISD at grade 3+ pain. Adrenergic activity, estimated from plasma and urinary catecholamines, appeared to be increased in these patients before drug treatment and was not altered during treatment. It is concluded that propranolol, ISD, and the combination of these drugs all improve exercise performance in patients with angina. Although the combination of drugs could not be shown to produce a greater increase in exercise performance than either drug alone, the combination effected a greater overall clinical improvement. ANGINA PECTORIS is a manifestation of a transient imbalance between oxygen delivery and oxygen requirements in a relatively ischemic area of the myocardium. This imbalance is the result of the increased myocardial oxygen requirements that occur as a consequence of temporary alterations in cardiac performance during an anginal at-tack. These alterations in cardiac function are manifested as increments in heart rate and blood pressure which precede the onset of anginal and are usually related to heightened levels of adrenergic activity. It is for these reasons that pharmacological measures to interfere with this activity first seemed a logical approach to the treatment of angina.2 Propranolol, an effective beta-adrenergic receptor-blocking drug, represents one such potential therapeutic agent, and the conclusions of several studies have suggested its efficacy. [3] [4] [5] [6] [7] Evaluation of drugs in angina pectoris has been imperfect because subjective improvement in response to therapy is difficult to estimate in this disease, and objective methods of testing have often not been adequately performed. It is possible, however, to establish a standardized exercise testing program using the treadmill wherein the variability in level of exercise necessary to produce angina can be minimized. 4 8 Robinson9 has shown recently that, regardless of the type of objective stress test utilized, the onset of angina is dependent upon a predictable and reproducible critical level of the product of systolic blood pressure times heart rate in the individual patient. Utilization of a combination of both the exercise performance and the product of blood pressure times heart rate should provide a more substantial means of assessment of the response of a therapeutic agent in this disease.
Additional
The present study was undertaken to examine the therapeutic response to propranolol in patients with angina, utilizing the objective criteria of exercise performance on the treadmill compared to the blood pressure and heart rate changes as well as subjective improvement of the patient. In addition, we evaluated the effects of isosorbide dinitrate (ISD) alone and in combination with propranolol. It has recently been suggested that the combination of propranolol and either nitroglycerin10 or ISD,11 acutely administered sublingually prior to testing, produced a synergistic effect on the exercise capacity. Therefore, we were interested to determine whether the chronic oral administration of ISD also produced a synergism with propranolol. In an attempt to correlate the level of adrenergic activity in the patients with the effects of these drugs, plasma catecholamine concentrations were measured before and during angina induced by the treadmill testing. Daily urinary catecholamine excretions were also determined on the various combinations of drugs.
Methods
Twelve patients were studied, all of whom had had angina pectoris for at least 6 months. These patients were selected because of the frequency of occurrence of angina, greater than 5 attacks weekly, and their willingness to undergo repetitive laboratory testing. In addition to the clinical history of angina, they had one or more of these objective findings: positive exercise electrocardiograms, abnormal resting electrocardiograms (ECG), and evidence of coronary artery disease on cineangiography (table 1) . Two patients had had Vinberg operations. Seven patients had a history of myocardial infarction, and five of these showed evidence of old infarction on the electrocardiogram. No patient had overt evidence of congestive heart failure at the time of study, although two patients gave a history of previous failure and were on digitalis. Nine patients were males and three were females, the average age being 53 years. Miscellaneous associated medical diagnoses are listed in table 1 .
The patients were taken off all anti-anginal drugs and were studied during a control period until they were stable clinically and had performed consistently on the treadmill. Patients were exercised five to six times over an average period of 18 days before being placed on any therapy. During the entire study period the patients kept a record of their number of attacks of angina, amount of nitroglycerin consumed, and severity of attacks, which they were asked to rate on a scale of grade 1+ to 4+. Symptomatic response to therapy was evaluated by a change either in number of attacks or amount of nitroglycerin consumed and rated on a scale (table 2) . Blood sugar, electrolytes, liver function tests, and chest x-rays were obtained on all patients during control and propranolol periods, and these were unchanged during therapy. The patients were evaluated subjectively and objectively, and all ECGs were examined by the same observer throughout the study and again at the end of the study. Seven of eight patients, not receiving digitalis and treated with all the drugs, had significant S-T depression which was analyzed in regard to change in response to therapy.
Treadmill testing was done at a 10% grade starting at a speed of 1.2 mph and increasing the speed 0.6 mph every 3 min until the subjects were stopped by grade 3+ out of grade 1 to 4+ pain or fatigue. Each patient served as his own control and walked until he reached the same amount of pain during each exercise study. Exercise performance was evaluated as the summation of speed multiplied by time at each exercise level, thereby giving more credit to an increase in walking time at faster rather than slower speed. The standard deviation of the duplicate performances of the exercise testing was 16.2%. Electrocardiogram and blood pressure were monitored continually on an oscilloscope, and recordings were made every 1.5 min on a polygraphic recorder. Blood pressure was measured Samples were drawn at rest, during exercise prior to onset of pain, and at grade 3+ pain immediately after stopping exercise. Urinary norepinephrine and epinephrine determinations were done fluorometrically14 on two occasions during each drug period. Plasma catecholamines were also determined on eight normal subjects at levels of exercise comparable to those achieved in the patients and also at a substantially higher level. In two of these, studies were also done during administration of 160 mg of propranolol daily.
Analysis of variance on randomized blocks was used to determine the statistical significance of the effects of treatments on the physiological data, the ECG changes, and plasma and urinary catecholamines. Comparison of means in the placebo group with normal subjects was made using Cochran's conservative modification of the two-sample t-test. 15 In two cases, P.P. and P.B., only control or placebo observations were obtained and these were assumed to be the same for purposes of analysis.
Results

Physiological Data
The physiological data obtained during exercise in all 12 patients appears in table 3 . Average values of these data are also reproduced for 10 of these 12 patients in whom it was possible to compare responses to all five treatment schedules. The heart rate was reduced significantly by propranolol at rest and Circulation, Volume XXXIX, February 1969 during exercise (P < 0.01), while the addition of ISD produced no consistent alteration in heart rate in the patients treated with either placebo or propranolol. A small but significant reduction in blood pressure was observed with propranolol (P < 0.05), whereas the addition of ISD to placebo or propranolol treatment produced little further alteration in blood pressure. Thus, the pressure-rate index (systolic BP x HR x 10-2) was lowered significantly during administration of propranolol both during rest and exercise (P <0.01). The addition of ISD produced little change in these values, with only a minimal reduction at rest and a minimal increase during exercise. In contrast to the physiological measurements, the exercise performance was significantly increased both by propranolol and by ISD (P <0.05). The combination of these two drugs produced a slightly greater performance at both grades 1+ and 3+ pain than either drug alone, but the difference was not statistically significant.
The relative decreases in pressure-rate index during use of propranolol were 31.5% at rest, 31.2% at grade 1+ pain, and 28.6% at grade 3+ pain ( fig. 2) . With propranolol plus ISD, the decreases were similar, whereas ISD alone produced only minimal changes. Relative changes from placebo in pressure-rate index (systolic BP X HR X 10-2) and exercise performance Abbreviations: Pe = placebo; Pr = propranolol; ISD = isosorbide dinitrate; R = rest; 1 + and 3+ = pain levels. *P < 0.05 = significantlv different from placebo at same pain level. there was improvement subjectively in eight of 12 patients and objectively in nine of 12. A correlation between these evaluations was observed in six of these 12 patients. With ISD alone we observed improvement subjectively in five of 10 patients and objectively in seven of 10 patients with a correlation occurring between subjective and objective evaluations in four of 10 patients. With the combination of drugs, all patients were improved subjectively and seven of 10 objectively, with a correlation between the evaluations occurring in seven of 10 patients. Utilizing both methods of evaluation, it was possible to derive a combined index of therapeutic responses (table 2B) . With propranolol, nine of 12 patients were improved and three were worse. With ISD, seven of 10 patients were Csrculation, Volume XXXIX, February 1969 improved and three were worse, while with the combination of drugs all 10 patients were moderately or much better and none were worse.
Side Effects
Five of 12 patients complained of drowsiness while on propranolol, and four of these had continued drowsiness on propranolol plus ISD. Three patients had gastrointestinal cramps and diarrhea with propranolol, and in two of these, who had a history of ulcer or hiatal hernia, administration of the drug was discontinued after the study was concluded. One patient, L. K., developed four episodes of amnesia while receiving propranolol which subsequently did not reoccur. No patient developed overt signs of congestive heart failure or change in heart size on chest propranolol. This improved after the drug was discontinued.
Assessment of Adrenergic Function
The extent of adrenergic blockade was substantial in all patients treated with propranolol. This was established by determining the amount of isoproterenol necessary to increase the heart rate by 20 beats per minute before and during treatment. The average amount required during the control period was 1.6 ug/min, whereas propranolol administration increased this to at least 10 daily, it was shown by isoproterenol sensitivity to be sufficiently effective to produce at least a sevenfold change in the response to this agonist. Propranolol alone increased exercise performance more than 10% in nine of 12 patients. In these, the relative improvement in performance on the treadmill was variable, ranging from 10 to 160%. ISD alone also increased exercise performance by more than 10% in seven of 10 patients. In these patients the relative improvement ranged from 13 to 342%. The combination of both drugs resulted in the same incidence of improved performance, although the magnitude of the change was slightly greater than that observed from either drug alone. S-T segment depression on exercise at grade 3+ pain was significantly diminished only by propranolol or by the combination of propranolol and ISD, but not by ISD alone. However since S-T depression was not significantly altered from that observed on placebo at comparable pressurerate indices, it is suggested that no actual improvement in myocardial oxygen delivery was effected by the drug. Subjectively, utilizing amounts of nitroglycerin consumed or numbers of anginal attacks reported, there was greater than 20% improvement in eight of 12 patients from propranolol and in five of 10 from ISD whereas the combination produced greater than 40% improvement in all 10 patients (table 2) . Frequently no relation was seen between the objective and subjective response to therapy in an individual patient. In an attempt to compare therapeutic efficacy of the drug regimens, a combined subjective and objective response was utilized (table 2) . This indicated that nine of 12 patients on propranolol and seven of 10 on ISD were improved, whereas on the combination all 10 were definitely improved.
In comparing these results with other recent reports of pharmacological treatment of angina pectoris, certain observations are worthy of comment. A beneficial effect of propranolol could not be demonstrated objectively in all patients in our study, and this was the experience in previous studies." ' 10 work.'9 However, this index is a useful rough approximation and previously has been employed in clinical evaluations of angina.7 In our studies propranolol alone and in combination with ISD markedly reduced this index at rest and during all levels of exercise so that, even though achieving a greater exercise performance at grade 3+ pain, the patients actually developed a significantly smaller pressure-rate index. The fact that these patients were stopped at the same amount of pain at the lower index suggests an alteration of other components of cardiac work such as an increase in ventricular volume which has been shown to occur with the administration of propranolol.'9 It was anticipated that the addition of ISD would decrease the dimensional changes of the heart produced by propranolol and lead to a greater increase in exercise performance. Nitrates The plasma norepinephrine, utilized as an index of adrenergic activity during exercise, was increased significantly with exercise that produced grade 3+ pain in the patients, whereas in normal subjects far more exercise was required before an increase occurred. Although these observations during exerciseinduced angina are consistent with previous reports, the magnitude of the rise in norepinephrine was not as striking.21' 22 Also, our findings indicate that during exercise prior to the onset of pain no significant increase in plasma norepinephrine was observed. It is notable that although the plasma norepinephrine was somewhat higher with pain during propranolol, the increase was seen at greater exercise performance, and it might be expected that this could account for the higher norepinephrine. Similarly, no consistent alteration was observed in catecholamine excretion during propranolol. Thus, there does not seem to be any evidence for a compensatory increase in norepinephrine release to overcome the adrenergic receptor blockade produced by propranolol. Further support for this conclusion is derived from study of two of our normal subjects who received 160 mg of propranolol daily for 3 days, but whose plasma norepinephrine response to exercise was the same as it was before the drug was given. The elevation of daily norepinephrine excretion Circulation, Volume XXXIX, February 1969 in the patients with angina compared to that of normal subjects suggests an augmented level of adrenergic activity in these patients. This activity appears to have been episodic since plasma norepinephrines were consistently in the normal range prior to the exercise testing. Although some relation between plasma or urinary catecholamines and the response to beta-adrenergic blockade was anticipated, no such correlation could be established in the patients studied.
